These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 27145445)

  • 1. Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.
    Golde TE
    J Neurochem; 2016 Oct; 139 Suppl 2(Suppl 2):224-236. PubMed ID: 27145445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review on Alzheimer's disease: Inhibition of amyloid beta and tau tangle formation.
    Ashrafian H; Zadeh EH; Khan RH
    Int J Biol Macromol; 2021 Jan; 167():382-394. PubMed ID: 33278431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease.
    Zhang W; Smith N; Zhou Y; McGee CM; Bartoli M; Fu S; Chen J; Domena JB; Joji A; Burr H; Lv G; Cilingir EK; Bedendo S; Claure ML; Tagliaferro A; Eliezer D; Veliz EA; Zhang F; Wang C; Leblanc RM
    Acta Biomater; 2024 Jul; 183():341-355. PubMed ID: 38849023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Abeta and tau in Alzheimer's disease, an early interim report.
    Golde TE; Petrucelli L; Lewis J
    Exp Neurol; 2010 Jun; 223(2):252-66. PubMed ID: 19716367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
    Suzuki N; Hatta T; Ito M; Kusakabe KI
    Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β and Tau at the Crossroads of Alzheimer's Disease.
    Gallardo G; Holtzman DM
    Adv Exp Med Biol; 2019; 1184():187-203. PubMed ID: 32096039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
    Long JM; Holtzman DM
    Cell; 2019 Oct; 179(2):312-339. PubMed ID: 31564456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
    Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
    Dunys J; Valverde A; Checler F
    J Biol Chem; 2018 Oct; 293(40):15419-15428. PubMed ID: 30143530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates in Alzheimer's disease: from basic research to diagnosis and therapies.
    Liu E; Zhang Y; Wang JZ
    Transl Neurodegener; 2024 Sep; 13(1):45. PubMed ID: 39232848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
    Boutajangout A; Wisniewski T
    Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease: from pathogenesis to disease-modifying approaches.
    Galimberti D; Scarpini E
    CNS Neurol Disord Drug Targets; 2011 Mar; 10(2):163-74. PubMed ID: 21222635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer disease therapy--moving from amyloid-β to tau.
    Giacobini E; Gold G
    Nat Rev Neurol; 2013 Dec; 9(12):677-86. PubMed ID: 24217510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.
    Bateman RJ; Klunk WE
    Neurotherapeutics; 2008 Jul; 5(3):381-90. PubMed ID: 18625449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.